News

Featured news from NHIVNA

HIV-related news from NAM

Anal cancer screening may be appropriate for all women with HIV, French researchers suggest
Keith Alcorn, 2013-10-17 19:40:00

Women living with HIV had a higher risk of anal pre-cancerous changes than cervical changes linked to human papillomavirus (HPV), French researchers reported at the 14th European AIDS Conference in Brussels. They suggested that all women with HIV ought to be screened routinely for pre-cancerous changes in the anal canal.

The study also found that there was no association between pre-cancerous changes in the anal canal and a prior history of anal intercourse, but a strong association with a previous history of cervical HPV-related disease.

Clinical management guidelines for women with HIV recommend routine screening for pre-cancerous cervical changes according to national guidelines. There is no consensus regarding anal screening in women with HIV.

French researchers carried out a study to determine the prevalence of anal HPV infection and pre-cancerous changes in the anus among women with HIV participating in a national cohort study. The study recruited 319 women who agreed to anal HPV screening, of whom 171 (54% of the cohort) consented to an anal examination by a proctologist. Women who declined to take part in the anal examination had significantly higher CD4 counts, a longer duration of HIV infection and a higher frequency of viral suppression on antiretroviral treatment (98% of all participants were taking antiretroviral therapy) .

The median age of women who took part in the study was 47 years, the median CD4 cell count 655 cells/mm3 and 36% were from sub-Saharan Africa. Thirty-six per cent of the women reported a prior history of receptive anal intercourse.

Women underwent cervical PAP and HPV testing and anal cytology and HPV testing. High-resolution anoscopy was performed in order to identify the stage of any lesions in the anal canal.

Anoscopy diagnosed anal lesions in 34% of women (21 of 171 samples were excluded due to unsatisfactory sampling). Low-grade (AIN-1) lesions were diagnosed in 21% of women and high grade (AIN 2-3) intraepithelial neoplasia in 13% of women. One woman was diagnosed with anal cancer. A high prevalence of HPV types associated with cancer was detected (57%). Two-thirds of women with high-risk HPV sub-types had more than one high-risk sub-type.

The sensitivity of high-resolution anoscopy to detect high-grade anal intraepithelial neoplasia was 76% and the specificity 61%.

By multivariate analysis high-grade anal intraepithelial neoplasia (HGAIN) was associated with a history of cervical low-grade intraepithelial lesions (relative risk 4.0, 95% confidence interval 1.0-15.8, p = 0.05). HGAIN was more strongly associated with the detection of HPV-16 (relative risk 15.6, 95% confidence interval 5.2-46.8, p<0.0001).

In a comparison of cervical and anal cytology and HPV testing results, both low-grade lesions and high-risk HPV types were found to be more common in the anal canal.

This study was cross-sectional in design, and so evaluated only the prevalence of HPV-associated lesions and high-risk HPV types. The tendency of low-grade cervical lesions to regress during follow-up has led to uncertainty regarding the natural history of HPV-related anal lesions, so a prospective study which followed women for several years might lead to different estimates of risk. Nevertheless, the French research group concluded that their findings suggest that anal HPV screening may be warranted in all women with HIV.

Source:1